Revelation Biosciences, Inc. Common Stock (REVB) Stock Price

REVBStock
$1.0590.59%52W
Market Cap$4.18M
P/E
PEG Ratio
Div yield
Beta-0.06

REVB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-34.15%
Price vs S&P 500 (4W)1.40%
VGM Score26.29

REVB Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.83-$0.87-4.82%(-$0.04)
Q1 2026-$1.15-$2.71-135.65%(-$1.56)
Q4 2025-$3.66-$1.65+54.92%(+$2.01)
Q3 2025-$5.34-$7.08-32.58%(-$1.74)
Q2 2025-$24.60-$28.04-13.98%(-$3.44)

REVB Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
REVBRevelation Biosciences, Inc. Common Stock
D$1.05
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Revelation Biosciences, Inc. Common Stock

Revelation Biosciences is a clinical-stage biotech company developing immunology-based treatments using Gemini, a proprietary TLR4 agonist designed to modulate inflammatory responses for therapeutic benefit. The company's pipeline includes three Gemini-based programs: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.